Macrophage Regulation of Ozone-Induced Lung Inflammation

ConditionRespiratory Viral Infection

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-55

SponsorRobert Tighe, MD

About this trial

The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.

Eligibility criteria

Qualifiers

Individuals between 18-55 yrs. of age (No subject will be excluded from the study on the basis of gender or ethnicity)

Individuals with knowledge of prior respiratory viral infection history allowing them to be segregated into one of three cohorts

Cohort 1 - No history of respiratory viral infection (defined as no symptoms consistent with respiratory viral infection nor history of a positive respiratory viral test)

Cohort 2 - Documented mild respiratory viral infection (a positive test, either PCR- or antigen-based) but with mild to no symptoms and no evidence of a lower respiratory tract infection (including no hospitalization, and no oxygen use)

Disqualifiers

Individuals with prior respiratory viral pneumonia who have ongoing respiratory symptoms, are still using supplemental oxygen, or have abnormal lung function

Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years

Pregnant women and women who are presently lactating.

Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks

Trial design

Treatments tested in this trial

Ozone

Treatment groups

100 Participants

are divided into 3 treatment groups

Sponsors and collaborators

Robert Tighe, MD

Lead sponsor

Duke University

Sponsor institution

National Institutes of Health (NIH)

Collaborator

National Institute of Environmental Health Sciences (NIEHS)

Collaborator

Source ClinicalTrials.gov